Johnson & Johnson Reports Strong Q1 2024 Results: Darzalex Nears $2.7B, Carvykti Revenue Doubles

Apr 17, 2024 08:14 CST Updated 08:14

Johnson & Johnson

Medical Device R&D and Manufacturer

April 16,Johnson & JohnsonAnnouncing Q1 2024 Performance: Quarterly Revenue of $21.384 Billion, a Year-on-Year Increase of 2.3%; Including Innovative Pharmaceutical Business Q1 Revenue of $13.562 Billion, a Year-on-Year Increase of 1.1%.

Johnson & JohnsonInnovative Drug BusinessMainly focusing on autoimmune diseases, oncology, neuroscience, infectious diseases, pulmonary hypertension, cardiovascular and metabolic disorders.

Revenue in the autoimmune sector reached $4.247 billion, representing a year-on-year increase of 3.3%.Among them, Stelara, which has been on the market for more than a decade (Ustekinumab) remains Johnson & Johnson's best-selling autoimmune product, with Q1 revenue of $2.451 billion, although the growth rate has slowed to a mere 0.3%.Taking over the batonTremfya(Guselkumab) achieved sales of $808 million with a growth rate of 26.3%.

Oncology Sector Q1 Performance Strong, Revenue $4.814 Billion, Up 17.1% Year-over-Year. Specifically, Carvykti (Cilta-cel) achieved double the revenue compared to the same period last year, reaching 1.57 billion US dollars. Darzalex (Daratumumab) maintained a high level of performance, increasing by 18.9% year-over-year to reach $2.692 billion, with breaking $10 billion for the entire year now certain. Imbruvica (Ibrutinib) andZytiga(Abiraterone) sales continued to decline, reaching $784 million and $181 million, respectively.

Neuroscience Segment Revenue in Q1 2024 Remains Flat at $1.803 Billion Compared to Last Year.The pulmonary arterial hypertension sector also performed well, increasing by 20.2% year-over-year to reach USD 1.049 billion.

Looking ahead, Johnson & Johnson forecasts full-year 2024 sales to be between $88.7 billion and $89.1 billion, higher than the previously expected range of $88.2 billion to $89.0 billion.

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position.For reprint, please leave a message to the WeChat Official Account backend or send a message, and indicate the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.

Exciting Preview

Offline Salon

↑ Long press to scan the QR code and sign up for the event ↑